Today's episode deals with a question from listener Michael, via LinkedIn: What in the world has happened with CSL? Downgrading guidelines, some board member transitions, vaccine business segment demerger, and a huge drop in stock price! Steve Wheen, Head of Healthcare, and Managing Director of Equity Research at Jarden, talks to Sean Aylmer about CSL and the rest of the healthcare sector. This is general information only. Seek professional advice before making investment decisions. Find out more: https://fearandgreed.com.au/ See omnystudio.com/listener for privacy information.
